Innovating Works

ImmuNiche

Financiado
Identifying spatial determinants of immune cell fate commitment
The complex architecture of the mammalian hematopoietic system has been studied for decades, yet the molecular mechanisms underlying cell fate commitment remain poorly understood. Although cytokine signals are major determinants o... The complex architecture of the mammalian hematopoietic system has been studied for decades, yet the molecular mechanisms underlying cell fate commitment remain poorly understood. Although cytokine signals are major determinants of hematopoietic cell fate, only few niches of stem and progenitor cells have been characterized. Here, we propose to resolve the cell type composition of mouse bone marrow by integrating single-cell RNA-seq with high-resolution spatial analysis of gene expression in tissue sections, visualizing ~250 cell type specific markers by multiplexed single-molecule RNA fluorescent in situ hybridization. This approach will reveal preferential co-localization of hematopoietic cells with other bone marrow-resident cell types, and globally predict niches of hematopoietic progenitor sub-types to pinpoint microenvrionmental determinants of hematopoietic cell fate. Based on this reference we will investigate the role of the microenvironment in the pathogenesis of myelodysplastic syndromes (MDS), representing one of the most frequent blood cell malignancies, commonly giving rise to leukaemia with poor prognosis. To investigate conservation of microenvironmental determinants of normal and malignant hematopoietic differentiation in human, we will apply the same strategy to healthy donors and human MDS patients and compare predicted cell types, differentiation trajectories, and niche interactions to those derived from healthy mice and murine MDS models. This approach will reveal conserved niche regulators of cell fate commitment involved in disease pathogenesis, which we will functionally analyse in murine models to identify novel therapeutic targets for prevention and treatment of MDS. Our approach represents a blueprint for investigating human malignancies of under-characterized tissues by applying cutting-edge high-resolution techniques in combination with advanced computational methods to jointly analyse the murine model and human patient microenvironment. ver más
31/12/2026
2M€
Duración del proyecto: 94 meses Fecha Inicio: 2019-02-14
Fecha Fin: 2026-12-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2019-02-14
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
Presupuesto El presupuesto total del proyecto asciende a 2M€
Líder del proyecto
JULIUSMAXIMILIANSUNIVERSITAT WURZBURG No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5